CPC289 is a CriPec®-based nanoparticle incorporating dexamethasone, an approved corticosteroid therapeutic for the treatment of inflammation. Compared with standard systemic dexamethasone treatments, CPC289 is designed to target a chronic inflammation site more effectively and enable improved sustained drug release.
By specifically targeting the site of chronic inflammation with a defined drug payload, CPC289 aims to overcome the low efficacy, limited half-life and multiple off-target toxicities routinely seen with dexamethasone.
Furthermore, additional studies suggest that this effect does not seem to be specific for CPC289, but is expected to hold true for all corticosteroids.
CPC289 is ready for pre-clinical development and is available for partnering.